HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix. It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution. The company was formerly known as Hans Medical Corp. and changed its name to HansBiomed Corporation in June 2000. HansBiomed Corporation was founded in 1993 and is based in Seoul, South Korea.
Stock data | 2023 | Change |
---|---|---|
Price | $7.70 | N/A |
Market Cap | $68.94M | N/A |
Shares Outstanding | 8.95M | -9.17% |
Employees | 254.00 | N/A |
Shareholder Equity | 49.95B | 5.26% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 1.17 | N/A |
P/B Ratio | 0.00 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0004 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $58.82M | N/A |
Earnings | -$18.16M | N/A |
Gross Margin | 0.5783 | N/A |
Operating Margin | -0.0532 | N/A |
Net income margin | -0.3087 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $92.25M | N/A |
Total Debt | $31.01M | N/A |
Cash on Hand | $5.31M | N/A |
Debt to Equity | 0.0011 | -18.32% |
Cash to Debt | 0.1713 | -29.33% |
Current Ratio | 0.7723 | 5.74% |